CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.

ABSTRACT: Adoptive cell therapy has received a great deal of interest in the treatment of advanced cancers that are resistant to traditional therapy. The tremendous success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells in the treatment of cancer, especially hematological cancers, has exposed CAR's potential. However, the toxicity and significant limitations of CAR-T cell immunotherapy prompted research into other immune cells as potential candidates for CAR engineering. NK cells are a major component of the innate immune system, especially for tumor immunosurveillance. They have a higher propensity for immunotherapy in hematologic malignancies because they can detect and eliminate cancerous cells more effectively. In comparison to CAR-T cells, CAR-NK cells can be prepared from alloge

SUBMITTER: Marofi F 

PROVIDER: S-EPMC8252313 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature